JAMA Network
About The Study: The use of plasma circulating tumor DNA testing before tissue diagnosis among patients with suspected advanced lung cancer may expedite biomarker testing and accelerate time to treatment.
Authors: Natasha B. Leighl, M.D., of the University Health Network in Toronto, Ontario, Canada, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi: 10.1001/jamanetworkopen.2023.25332)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
